Viking Therapeutics Jumps 36%, Best Day Since February 2024

A move of this size without any disclosed catalyst is the story. Single-day gains of this magnitude in a clinical-stage biotech usually reflect a specific event — data, a deal, or a regulatory signal — so the absence of detail leaves the driver unidentified. That matters for anyone tracking the name, because it makes the move difficult to interpret as either durable or technical. Whether the company or another party clarifies what prompted the session is the open question.